Atazanavir Sulfate Capsule
NDC Package 0093-5527-06
Package Information
Atazanavir Sulfate capsules is atazanavir capsules are indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and in pediatric patients 6 years and older weighing at least 15 kg.Limitations of Use:Atazanavir capsules are not recommended for use in pediatric patients below the age of 3 months due to the risk of kernicterus [see Use in Specific Populations (8.4)].Use of atazanavir capsules with ritonavir in treatment-experienced patients should be guided by the number of baseline primary protease inhibitor resistance substitutions [see Microbiology (12.4)]. This formulation utilizes a capsule delivery system. Marketed by Teva Pharmaceuticals Usa, Inc., this product is identified by NDC 0093-5527 and is authorized under FDA application ANDA091673.
Identification & Billing
Clinical Specifications
- Cytochrome P450 2C8 Inhibitors - [MoA] (Mechanism of Action)
- Cytochrome P450 3A Inhibitors - [MoA] (Mechanism of Action)
- Cytochrome P450 3A4 Inhibitors - [MoA] (Mechanism of Action)
- HIV Protease Inhibitors - [MoA] (Mechanism of Action)
- Protease Inhibitor - [EPC] (Established Pharmacologic Class)
- UDP Glucuronosyltransferases Inhibitors - [MoA] (Mechanism of Action)
- UGT1A1 Inhibitors - [MoA] (Mechanism of Action)
Regulatory & Marketing
Hierarchy Structure
- 0093 - Teva Pharmaceuticals Usa, Inc.
- 0093-5527 - Atazanavir Sulfate
- 0093-5527-06 - 60 CAPSULE in 1 BOTTLE
- 0093-5527 - Atazanavir Sulfate
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 0093-5527-06 identifies a specific commercial package of 60 capsule in 1 bottle of Atazanavir Sulfate, a human prescription drug labeled by Teva Pharmaceuticals Usa, Inc.. This capsule is formulated for oral use and contains atazanavir sulfate as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Teva Pharmaceuticals Usa, Inc. on December 27, 2017.
How is this Teva Pharmaceuticals Usa, Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 00093552706. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 60 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Labeler segment to maintain the 5-4-2 structure.